Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Lamb

Nurse Practitioner Ocala, FL Nurse Practitioner

NPI 1356607196 CMS profile 10601798

2651 Sw 32Nd Pl, Ocala, FL 34471

Open in the dashboard

General payments

$3,930

176 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Lamb of Ocala, FL is reported in the CMS Open Payments database as having received $3,930 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,362 56
2024 General $806 29
2023 General $531 22
2022 General $688 37
2021 General $544 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Lamb
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michael Lamb were reported at $1,362. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michael Lamb Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $544 $135 $40–$426 $132
2022 $688 $152 $48–$470 $149
2023 $531 $166 $54–$529 $160
2024 $806 $173 $55–$556 $164
2025 $1,362 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $607 22 payments
  2. Merck Sharp & Dohme Corporation $443 24 payments
  3. Insmed, Inc. $363 19 payments
  4. Averitas Pharma Inc. $339 9 payments
  5. Theratechnologies Inc. $310 12 payments
  6. Aimmune Therapeutics, Inc. $264 10 payments
  7. ViiV Healthcare Company $182 7 payments
  8. Smith+Nephew, Inc. $180 7 payments
  9. Janssen Biotech, Inc. $164 11 payments
  10. AbbVie, Inc. $133 7 payments
  11. Other $944 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,907 174 payments
  2. Education $23 2 payments
Products named General payments · program years 2021–2025
  1. Arikayce $363 19 payments
  2. Qutenza $339 9 payments
  3. EGRIFTA $288 11 payments
  4. TROGARZO $286 11 payments
  5. DIFICID $277 16 payments
  6. VOWST $233 9 payments
  7. PIFELTRO $218 11 payments
  8. SYMTUZA $164 11 payments
  9. ZERBAXA $155 8 payments
  10. DELSTRIGO $153 9 payments
  11. Other $2,437 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

135

Median for Nurse Practitioner: 389

Drug cost

$130,828

Median for Nurse Practitioner: $21,885

Branded share of claims

40%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 24 $93,448
Efavirenz-Emtric-Tenofov Disop Efavirenz/Emtricit/Tenofovr Df Brand 12 $25,688
Vancomycin Hcl Generic 19 $5,442
Daptomycin Generic 12 $2,667
Ceftriaxone Ceftriaxone Sodium Brand 18 $2,190
Doxycycline Hyclate Generic 39 $1,246
Ciprofloxacin Hcl Generic 11 $147

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $229
$229 — —
Arikayce
  • Insmed, Inc. $53
$53 — —
MAVYRET
  • AbbVie, Inc. $22
$22 — —
EGRIFTA
  • Theratechnologies Inc. $21
$21 — —
TROGARZO
  • Theratechnologies Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record